Cas no 131933-18-1 (2-(2-Cyclohexylethoxy)adenosine)

2-(2-Cyclohexylethoxy)adenosine is a modified nucleoside derivative that serves as a valuable intermediate in medicinal chemistry and biochemical research. Its structure, featuring a cyclohexylethoxy substitution at the 2-position of adenosine, enhances lipophilicity and may influence binding affinity to adenosine receptors or other biological targets. This compound is particularly useful for studying structure-activity relationships in nucleoside-based therapeutics, including potential applications in cardiovascular or neurological research. The cyclohexyl moiety contributes to improved metabolic stability compared to unmodified adenosine derivatives. It is typically employed in controlled research settings, requiring proper handling due to its specialized nature. The compound's purity and well-defined structure make it suitable for mechanistic studies and targeted drug discovery efforts.
2-(2-Cyclohexylethoxy)adenosine structure
131933-18-1 structure
Product Name:2-(2-Cyclohexylethoxy)adenosine
CAS No:131933-18-1
MF:C18H27N5O5
MW:393.437484025955
CID:157535
Update Time:2025-10-21

2-(2-Cyclohexylethoxy)adenosine Chemical and Physical Properties

Names and Identifiers

    • Adenosine,2-(2-cyclohexylethoxy)-
    • 2-(2-Cyclohexylethoxy)adenosine
    • 2-(1,1-DIFLUOROPROPYL)-1,3-DIFLUOROBENZENE
    • 2-[2-(cyclohexyl)ethoxy]-adenosine
    • SHA-91
    • WRC 0013
    • Inchi： 1S/C18H27N5O5/c19-15-12-16(22-18(21-15)27-7-6-10-4-2-1-3-5-10)23(9-20-12)17-14(26)13(25)11(8-24)28-17/h9-11,13-14,17,24-26H,1-8H2,(H2,19,21,22)/t11-,13-,14-,17-/m1/s1
    • InChI Key： VHMUQIWMOXQFBP-LSCFUAHRSA-N
    • SMILES： O1[C@H](CO)[C@H]([C@H]([C@@H]1N1C=NC2C(N)=NC(=NC1=2)OCCC1CCCCC1)O)O

Computed Properties

  • Exact Mass: 393.20100
  • Monoisotopic Mass: 393.201219
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 4
  • Hydrogen Bond Acceptor Count: 5
  • Heavy Atom Count: 28
  • Rotatable Bond Count: 6
  • Complexity: 511
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 4
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 2.4
  • Topological Polar Surface Area: 149

Experimental Properties

  • Density: 1.67
  • Boiling Point: 719°C at 760 mmHg
  • Flash Point: 388.7°C
  • Refractive Index: 1.75
  • PSA: 148.77000
  • LogP: 0.95040

2-(2-Cyclohexylethoxy)adenosine Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
C987920-100mg
2-(2-Cyclohexylethoxy)adenosine
 131933-18-1
100mg
 $196.00 2023-05-18
TRC
C987920-1g
2-(2-Cyclohexylethoxy)adenosine
 131933-18-1
1g
 $1533.00 2023-05-18

2-(2-Cyclohexylethoxy)adenosine Suppliers

NewCan Biotech Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:131933-18-1)2-(2-Cyclohexylethoxy)-Adenosine
Order Number:NC9177
Stock Status:
Quantity:10g
Purity:97%
Pricing Information Last Updated:Friday, 18 July 2025 16:16
Price ($):Price inquiry

2-(2-Cyclohexylethoxy)adenosine Related Literature

Additional information on 2-(2-Cyclohexylethoxy)adenosine

2-(2-Cyclohexylethoxy)adenosine: A Comprehensive Overview

2-(2-Cyclohexylethoxy)adenosine, also known by its CAS number 131933-18-1, is a structurally unique nucleoside analog that has garnered significant attention in the fields of pharmacology and medicinal chemistry. This compound is characterized by its adenosine backbone, which is a fundamental component of RNA, coupled with a cyclohexyl-substituted ethoxy group at the 2-position. The integration of the cyclohexyl moiety introduces interesting physicochemical properties, making it a promising candidate for various therapeutic applications.

The synthesis of 2-(2-Cyclohexylethoxy)adenosine involves a multi-step process that typically begins with the modification of adenosine. One of the key steps is the introduction of the ethoxy group, which is subsequently substituted with a cyclohexyl ring. This substitution not only enhances the lipophilicity of the molecule but also potentially improves its bioavailability. Recent advancements in synthetic chemistry have allowed for more efficient and scalable methods to produce this compound, ensuring its availability for preclinical and clinical studies.

One of the most compelling aspects of 2-(2-Cyclohexylethoxy)adenosine is its pharmacological profile. Studies have shown that this compound exhibits selective agonistic activity at adenosine receptors, particularly the A3 receptor. This selectivity is crucial as it minimizes off-target effects, which are often a challenge in drug development. The compound's ability to modulate adenosine signaling pathways makes it a potential candidate for treating conditions such as inflammation, pain, and certain neurological disorders.

Recent research has delved into the mechanisms underlying the therapeutic effects of 2-(2-Cyclohexylethoxy)adenosine. For instance, studies have demonstrated its anti-inflammatory properties through modulation of cytokine production and inhibition of pro-inflammatory pathways. Additionally, preclinical models have shown promise in pain management, particularly in chronic pain states where adenosine receptor activation has been implicated as a key therapeutic target.

The structural uniqueness of 2-(2-Cyclohexylethoxy)adenosine also lends itself to further chemical modifications. Researchers are actively exploring derivatives that could enhance potency, selectivity, and pharmacokinetic profiles. For example, modifications to the cyclohexyl group or the ethoxy linker are being investigated to optimize drug delivery and tissue penetration.

In terms of clinical translation, while 2-(2-Cyclohexylethoxy)adenosine has not yet entered human trials, preclinical data suggest a strong potential for therapeutic utility. Its safety profile appears favorable in animal models, with minimal adverse effects reported at therapeutic doses. However, further studies are required to fully characterize its long-term safety and efficacy.

The development of 2-(2-Cyclohexylethoxy)adenosine represents a significant advancement in nucleoside analog design. By leveraging modern synthetic techniques and insights from receptor pharmacology, this compound has emerged as a valuable tool in drug discovery. Its ability to target specific adenosine receptors opens new avenues for treating a wide range of diseases where adenosine signaling plays a critical role.

In conclusion, 2-(2-Cyclohexylethoxy)adenosine, with its CAS number 131933-18-1, stands at the forefront of nucleoside analog research. Its unique structure, favorable pharmacological properties, and potential therapeutic applications make it an exciting candidate for future drug development efforts. As research continues to unravel its mechanisms and optimize its properties, this compound holds great promise for advancing medical treatments across various therapeutic areas.

131933-18-1 (2-(2-Cyclohexylethoxy)adenosine) Related Products

Recommended suppliers
NewCan Biotech Limited
(CAS:131933-18-1)2-(2-Cyclohexylethoxy)-Adenosine
NC9177
Purity:97%
Quantity:10g
Price ($):Inquiry
Email